Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 1Peripheral Nervous System Diseases 1Head and Neck Neoplasms 1HER2-positive Breast Cancer 1Brain Neoplasms 1

Interventions

Cisplatin 141Radiotherapy 115Cetuximab 95Docetaxel 69Radiotherapy, Intensity-Modulated 55Carboplatin 47pembrolizumab 46Surveys and Questionnaires 46Paclitaxel 41Fluorouracil 39Radiation 29Blood Specimen Collection 27Drug Therapy 26Erlotinib Hydrochloride 23Nivolumab 21Surgical Procedures, Operative 17Standard of Care 16Magnetic Resonance Spectroscopy 16Radiosurgery 14Pemetrexed 14Gemcitabine 14Everolimus 13Celecoxib 13durvalumab 12Low-Level Light Therapy 12Immunohistochemistry 12Cyclophosphamide 12Capecitabine 12Amifostine 12Chemoradiotherapy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Head and Neck Neoplasms × Taxoids × Clear all
NCT05726370 2025-06-22

Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC

Dana-Farber Cancer Institute

Phase 2 Recruiting
28 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡